Abstract

To figure out the clinical value of edaravone in conjunction with nimodipine in treating aneurysmal subarachnoid hemorrhage. A total of 110 postoperative patients with aneurysmal subarachnoid hemorrhage, who received treatment at our center between May 2019 and May 2023, were categorized into an observation group (administered edaravone combined with nimodipine) and a control group (given nimodipine as a routine) based on different treatment methods. The efficacy status was the main outcome of this study, and safety was evaluated based on monitoring and recording of adverse events. Serum S-100 beta protein levels, clinical indicators of endothelin-1, middle cerebral artery blood flow velocity, as well as tumor necrosis factor-alpha, interleukin-6, and C-reactive protein levels were used as secondary outcomes. No significant difference was observed in the baseline characteristics of the two patient groups (p>0.05), and the occurrence of adverse events showed no significant variation between the two groups. The clinical indicators and inflammatory cytokine levels in both patient groups demonstrated substantial improvement when compared to their initial admission conditions, and the improvement was more notable in the observation group (p<0.05). In conclusion, the utilization of edaravone in combination with nimodipine as a treatment approach for patients following aneurysmal subarachnoid hemorrhage intervention surgery yields superior efficacy without an associated rise in adverse events. This treatment strategy possesses substantial clinical value and should be advocated for broader implementation.